Methods: The SP method of immunohistochemistry was carried out to detect the expression of RIPK3 protein in 30cases of normal skin tissues and 50 cases of cutaneous lichen planus lesions. Data analysis software was used to analyze the epidemiology characteristics.
Results: In 1854 patients from 2010 to 2018 in our hospital, the peak age of the patients diagnosed was 30-70 years old. There was no significant difference in sex ratio, but the mean age of diagnosis of male and female patients was statistically different. In normal skin tissues, RIPK3 protein was weakly expressed in the basal layer of the skin and in the bottom of the spinous layer, and it was mainly expressed in the nucleus. In the cutaneous lichen planus, RIPK3 protein was strongly expressed in the spinous layer, basal layer and part of the granular layer, and it was mainly expressed in the cytoplasm. The positive rate of the expression of RIPK3 protein in cutaneous lichen planus lesions was higher than that in normal skin tissues.
Conclusions: The age of onset of males is earlier than that of females in the pathogenesis of cutaneous lichen planus, but there is no difference in sex ratios. The high incidence age of males and females is in the middle and old stage. The transfer of RIPK3 protein as a transcription factor from the nucleus to the cytoplasm in cutaneous lichen planus may play a regulatory role in the pathogenesis of cutaneous lichen planus, which provides a significant thought and method for study of the pathogenesis of cutaneous lichen planus.
Keywords: Cutaneous lichen planus; skewed distribution; RIPK3; Transcription factor;
Receptor-interacting protein kinase 3 (RIPK3) is a member of the receptor-interacting protein kinase family of serine/ threonine protein kinases. The human RIPK3 gene is encoded on chromosome 14q11. The RIPK3 protein has a molecular weight of 53 kDa and encodes 518 amino acids. It contains a kinaseactive N-terminal kinase domain and a C-terminal RHIM domain that binds to multiple proteins [9].RIPK3 is highly expressed in lymphocytes, monocytes and NK cells, and is so expressed in liver cells, muscle cells, retinal cells, and epithelial cells [10-15]. RIPK3 is generally considered to be a key driver of necroptosis, which is a form of non-apoptotic programmed cell death. RIPK3 can rupture cell membranes by inducing programmed cell death to release intracellular compounds that activate immune function and promote inflammation [16-18]. In another case, RIPK3 can also activate downstream factors to promote inflammation independent of necroptosis [19-21].
In this study, we used immunohistochemistry to detect the expression level and expression localization of RIPK3 in cutaneous LP and perform statistical analysis. To explore the mechanism of RIPK3 in the development of cutaneous LP.
Year |
No. of patients |
Growth rate (%) |
Mean age |
||||
Male |
Female |
Total |
Male |
Female |
Total |
||
2010 |
40 |
37 |
77 |
40.15±16.08 |
41.08±15.31 |
40.60±15.83 |
|
2011 |
65 |
67 |
132 |
71 |
39.71±18.26 |
44.79±17.25 |
42.29±18.00 |
2012 |
98 |
99 |
197 |
49 |
41.47±18.36 |
45.94±14.06 |
43.72±16.53 |
2013 |
115 |
121 |
236 |
20 |
42.81±16.70 |
45.79±15.94 |
44.33±16.39 |
2014 |
93 |
101 |
194 |
-18 |
43.46±15.40 |
44.42±16.72 |
43.96±16.07 |
2015 |
106 |
94 |
200 |
3 |
42.97±16.77 |
48.96±15.67 |
45.79±16.49 |
2016 |
123 |
104 |
227 |
14 |
42.41±18.35 |
47.31±16.07 |
44.65±17.47 |
2017 |
165 |
122 |
287 |
26 |
42.29±16.97 |
45.43±15.76 |
43.63±16.51 |
2018 |
160 |
144 |
304 |
6 |
43.28±17.59 |
46.45±15.34 |
44.78±16.61 |
Total |
965 |
889 |
1854 |
42.37±16.67 |
45.95±15.81 |
44.09±16.67 |
Age in year |
No. of patients |
Percentage (%) |
||
Male |
Female |
Total |
||
0-20 |
92 |
57 |
149 |
8.04 |
21-40 |
362 |
259 |
621 |
33.49 |
41-60 |
347 |
404 |
751 |
40.51 |
61-80 |
158 |
166 |
324 |
17.47 |
80+ |
6 |
3 |
9 |
0.49 |
Total |
965 |
889 |
1854 |
100 |
Percentage (%) |
52.1 |
47.9 |
100 |
Groups |
n |
Expression grade |
Positive rate (%) |
|||
- |
+ |
++ |
+++ |
|||
Normal Skin |
30 |
11 |
16 |
3 |
0 |
63.33 |
Cutaneous LP |
50 |
5 |
5 |
17 |
23 |
90.00* |
In our study, we analyzed 1854 patients’ data from 2010 to 2018 in our hospital. It is proved that in the pathogenesis of lichen planus, the incidence is mostly in middle-aged and elderly people, and the mean age of onset was around 40 years old. The incidence rate was irrelevanttosex, but the age of onset is related. The incidence of men is in earlier age, which of women is later than that of men. Making 40-year old as a demarcation point, men are more likely to onset before the point and women are more likely to onset after it. The incidence of cutaneous LP has increased in recent years.
The receptor-interacting protein kinase 3 (RIPK3), is a member of the receptor-interacting protein kinase family of serine/threonine protein kinases and contains a unique C-terminal RHIM domain that is distinct from other family members[9]. RIPK3 is considered to be a component of the TNFR- 1 signaling complex, which activates NF-κB transcription factors and plays an important role in the process of necroptosis [16, 28, 29]. RIPK3 is highly expressed in lymphocytes, monocytes, and NK cells, and is also expressed in liver cells, muscle cells, retinal cells, and epithelial cells, and is abnormally expressed in inflammatory bowel disease, allergic enteritis, acute pancreatitis, Steven-Johnson syndrome, toxic epidermal necrolysis, ischemiareperfusion injury and neurodegeneration, which is implicated in the process of the disease[10-15]. In recent years, there has been ample evidence that RIPK3 plays an important role in the promotion of inflammatory diseases and abnormal proliferative skin diseases of keratinocytes [12, 13, 30, 31]. To the best of our knowledge, the role of RIPK3 in cutaneous LP has not been reported. In this study, we found that expression of RIPK3 is increased in human cutaneous LP lesions and is transferred from the nucleus to the cytoplasm. This suggests that RIPK3 may play a role in the pathogenesis of cutaneous LP, and this effect is achieved by nucleoplasmic transfer.
In summary, our data demonstrate that the age of onset of males is earlier than that of females in the pathogenesis of cutaneous lichen planus, but there is no difference in sex ratios. The high incidence age of males and females is in the middle and old stage. The pathogenesis of lichen planus is very complex, and the specific mechanism has not been elucidated. We have demonstrated that the expression of RIPK3 was changed in cutaneous lichen planus and the location was transferred, which suggests that RIPK3 plays a role in the pathogenesis of cutaneous lichen planus. But the specific mechanism still needs further research.
- Le Cleach L, Chosidow O. Lichen Planus. N Engl J Med. 2012;366:723-732.
- Patel GK, Turner RJ, Marks R. Cutaneous lichen planus and squamous cell carcinoma. European Academy of Dermatology and Venereology. 2003;17(1):97–116.
- Madhumita Bhattacharya, Kaur I, Kumar B. Lichen Planus: A Clinical and Epidemiological Study. The Journal of Dermatology. 2000;27(8):576-582.
- Lehman JS, Tollefson MM, Gibson LE. Lichen planus. 2009;48(7):682-694.
- Steffen C, Dupree.M. Louis-Frédéric Wickham and the Wickham's Striae of Lichen Planus. SKINmed: Dermatology for the Clinician. 2004;3(5):287-289.
- Pandhi D, Singal A, Bhattacharya SN. Lichen planus in childhood: a series of 316 patients. Pediatr Dermatol. 2014;31(1):59-67. doi: 10.1111/pde.12155
- Wagner G, Rose C, Sachse MM. Clinical variants of lichen planus. J Dtsch Dermatol Ges. 2013;11(4):309-319. doi: 10.1111/ddg.12031
- Tziotzios C, Lee JYW, Brier T, Saito R, Hsu CK, Bhargava K, et al. Lichen planus and lichenoid dermatoses: Clinical overview and molecular basis. J Am Acad Dermatol. 2018;79(5):789-804. doi: 10.1016/j.jaad.2018.02.010
- Pei Wen Yu, Betty CBH, Mary S, Jeff Q, Eva C, Xiang Xu, et al. Identification of RIP3, a RIP-like kinase that activates apoptosis and NFκB. Current Biology. 1999.
- Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M, et al. Phosphorylation-Driven Assembly of the RIP1-RIP3 Complex Regulates Programmed Necrosis and Virus-Induced Inflammation. Cell. 2009;137(6):1112-1123. doi: 10.1016/j.cell.2009.05.037
- Duprez L, Takahashi N, Van Hauwermeiren F, Vandendriessche B, Goossens V, Vanden Berghe T, et al. RIP Kinase-Dependent Necrosis Drives Lethal Systemic Inflammatory Response Syndrome. Immunity. 2011;35(6):908-918. doi: 10.1016/j.immuni.2011.09.020
- Han J, Zhong CQ, Zhang DW, Programmed necrosis: backup to and competitor with apoptosis in the immune system. Nature Immunology. 2011;12(12):1143-1149. doi: 10.1038/ni.2159
- Zhao Z, Zlokovic BV, RIPped for neuroinflammation. Cell Research. 2017;27(7):849-850.
- Oberst A, Green DR. It cuts both ways: reconciling the dual roles of caspase 8 in cell death and survival. Nature Reviews Molecular Cell Biology. 2011;12(11):757-763. doi: 10.1038/nrm3214
- Roychowdhury S, McCullough RL, Sanz-Garcia C, Saikia P, Alkhouri N, Matloob A et al. Receptor interacting protein 3 protects mice from high-fat diet-induced liver injury. Hepatology. 2016;64(5);1518-1533. doi: 10.1002/hep.28676
- Moriwaki K, Chan FKM. RIP3: a molecular switch for necrosis and inflammation. Genes & Development. 2013;27(15):1640-1649. doi: 10.1101/gad.223321.113
- Wallach D, Kang TB, Dillon CP, Green DR. Programmed necrosis in inflammation: Toward identification of the effector molecules. Science. 2016;352(6281):aaf2154. doi: 10.1126/science.aaf2154
- Wallach D, Kovalenko A, Kang TB. ‘Necrosome’-induced inflammation: must cells die for it? Trends in Immunology. 2011;32(11):505-509. doi: 10.1016/j.it.2011.07.004
- Lawlor KE, Khan N, Mildenhall A, Gerlic M, Croker BA, D'Cruz AA, et al. RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL. Nature Communications. 2015;6:6282. doi: 10.1038/ncomms7282
- Ciraci C, Sutterwala FS. Inhibitors of Apoptosis Proteins and IL-1β: A Tangled Relationship. Immunity. 2012;36(2):155-157. doi: 10.1016/j.immuni.2012.02.007
- Moriwaki K, Balaji S, McQuade T, Malhotra N, Kang J, Chan FK. The Necroptosis Adaptor RIPK3 Promotes Injury-Induced Cytokine Expression and Tissue Repair. Immunity. 2014;41(4):567-578. doi: 10.1016/j.immuni.2014.09.016
- Al-Hashimi I, Schifter M, Lockhart PB, Wray D, Brennan M, Migliorati CA, et al. Oral lichen planus and oral lichenoid lesions: diagnostic and therapeutic considerations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103 Suppl:S25 e1-12. DOI: 10.1016/j.tripleo.2006.11.001
- Carbone M, Arduino PG, Carrozzo M, Gandolfo S, Argiolas MR, Bertolusso G, et al. Course of oral lichen planus: a retrospective study of 808 northern Italian patients. Oral Dis. 2009;15(3):235-243. doi: 10.1111/j.1601-0825.2009.01516.x
- Bermejo-Fenoll A, Sánchez-Siles M, López-Jornet P, Camacho-Alonso F, Salazar-Sánchez N, et al. A retrospective clinicopathological study of 550 patients with oral lichen planus in south-eastern Spain. J Oral Pathol Med. 2010;39(6):491-496. doi: 10.1111/j.1600-0714.2010.00894.x
- Berger, Timothy G. Lichen Planus. JAMA Dermatology. 2015;151(3):356.doi:10.1001/jamadermatol.2014.5522
- Fox LP, Lightdale CJ, Grossman ME. Lichen planus of the esophagus: what dermatologists need to know. J Am Acad Dermatol. 2011;65(1):175-183. doi: 10.1016/j.jaad.2010.03.029
- D W. The Lichenoid Tissue Reaction. In: Weedon’s Skin Pathology. 3rd ed. Edinburgh: Elsevier Limited. 2010. 35.
- Meylan E, Tschopp J. The RIP kinases: crucial integrators of cellular stress. Trends Biochem Sci. 2005;30(3):151-159. DOI: 10.1016/j.tibs.2005.01.003
- Galluzzi L, Kepp O, Chan FK, Kroemer G. Necroptosis: Mechanisms and Relevance to Disease. Annual Review of Pathology: Mechanisms of Disease. 2017;12(1);103-130. DOI: 10.1146/annurev-pathol-052016-100247
- Schneider AT, Gautheron J, Feoktistova M, Roderburg C, Loosen SH, Roy S, et al. RIPK1 Suppresses a TRAF2-Dependent Pathway to Liver Cancer. Cancer Cell. 2017;31(1):94-109. doi: 10.1016/j.ccell.2016.11.009
- Daniels BP, Snyder AG, Olsen TM, Orozco S, Oguin TH, Stephen W.G. Tait, et al. RIPK3 Restricts Viral Pathogenesis via Cell Death-Independent Neuroinflammation. Cell. 2017;169(2):301-313.e11. doi: 10.1016/j.cell.2017.03.011